Long-term results of free flap cases using Nidek MK-2000 microkeratome in LASIK surgery
Session Details
Session Title: Investigations and Complications Management
Session Date/Time: Tuesday 13/09/2016 | 13:30-15:15
Paper Time: 14:44
Venue: Hall C3
First Author: : S.Altun TURKEY
Co Author(s): : U. Yolcu A. Ilhan A. Tas U. Erdem
Abstract Details
Purpose:
To report the clinical properties and visual outcomes of patients with free flap in laser in situ keratomileusis (LASIK) managed either with air drying with bandage contact lens or suturing.
Setting:
Clinical properties and outcomes of cases with free flap were retrospectively reviewed.
Methods:
Clinical properties and outcomes of cases with free flap were retrospectively reviewed in records of 2508 eyes of the 1275 consecutive LASIK cases at the Cornea and Refractive Surgery Dept. of Gulhane Military Medical Academy Hospital. All surgeries have been performed with Nidek MK-2000 microkeratome and Nidek EC CX2 laser system.
Results:
Twelve eyes of 12 patients had free flap (%0.48). Eight eyes were managed with single cross suture. In four eyes flaps were repositioned to its original position without suturing, air-dried at least 5 minutes and then a bandage contact lens was applied. There were no significant difference between cases managed with suturing or air drying with bandage contact lens in postoperative uncorrected visual acuity, best corrected visual acuity and Spherical equivalent values (p> 0.05 for all). At postoperative 6th month mean spherical equivalent were 0.72 ± 0,42 diopters and mean postoperative defocus equivalent were 0.08± 0.95 diopters. Over all, nine eyes gained one line of corrected distance visual acuity and 3 remained stable and none of them lost vision.
Conclusions:
Proper management can provide satisfactory visual and refractive outcomes in these cases. Although there is no significant difference in free flap developed cases managed with either suturing or air drying with bandage contact lens, suturing can cause moderate astigmatism.
Financial Disclosure:
NONE